The Latest Cardiac and Vascular News
TEL AVIV, Israel, June 9, 2025 /PRNewswire/ — Microtech, a wholly owned subsidiary of Medinol, is happy to announce the first U.S. implantations of its atrial-pressure microsensor. Two surgical implantations were performed on Friday, May 16, 2025, at New York-Presbyterian/Columbia…
TAMPA, Fla., June 6, 2025 /PRNewswire/ — The heart care experts at the Pepin Heart Institute, a part of AdventHealth Tampa, are now the first in the Tampa Bay area to complete 1,000 WATCHMAN ™ procedures, a minimally-invasive surgery that helps prevent stroke and cardiovascular death in…
NEW ORLEANS, LA, JUNE 6, 2025 – Findings from a phase three, randomized controlled clinical trial demonstrate the superiority of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) over autologous arteriovenous fistula (AVF) in high-risk patients with end-stage kidney disease (ESKD). These data highlight the potential of ATEV to address unmet needs […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax® Inc., a leader in heart valve innovation, today announced that the Indian Central Drugs Standard Control Organization (CDSCO) approved its TRIA™ Mitral Valve. Dolphin Life Science India LLP will locally manufacture the TRIA Mitral Valve in India. Foldax’s vision for its novel polymer heart valves is […]
Founding CEO Tripp Higgins To Become Chairman of the Board of Directors, Supporting the Leadership Transition As Finkelmeier Puts Operational Structure in Place to Meet Growing Demand SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate, the cardiac remote monitoring platform that leading healthcare providers trust, today announced the appointment of JR Finkelmeier as Chief Executive […]
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more…
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025.
KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025. “I am delighted to welcome Conor to our board of directors,” said Brian Webster, President and CEO of Kestra Medical Technologies. “He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE® system.” Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device solutions company dedicated to improving outcomes for people with heart failure. He previously held senior management roles at ResMed, including leading the cardiology business unit and chronic disease management solutions globally. Prior to ResMed, Mr. Hanley was co-founder and CEO of BiancaMed, a medical device company that was acquired by ResMed. Mr. Hanley earned a PhD in chemical engineering from the University of Pennsylvania and an MBA from INSEAD. His previous board experience includes Enterprise Ireland and chair of APC Ltd. and the Irish MedTech association. “I am honored to join the Kestra board of directors,” said Mr. Hanley. “Kestra is driving much-needed innovation in the wearable cardioverter defibrillator market, and I look forward to collaborating with the management team as the company scales its operations and delivers on its commitments to patients and prescribers.” About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com. CONTACT: Investor contact
Neil Bhalodkar
neil.bhalodkar@kestramedical.com
Media contact
Rhiannon Pickus
rhiannon.pickus@kestramedical.com
MINNEAPOLIS & WASHINGTON–(BUSINESS WIRE)–Vensana Capital, a leading medical technology-focused venture capital and growth equity investment firm, today announced the additions of Maria Berkman, MD, as Partner and Ross (Rusty) Segan, MD, as Venture Partner. Maria Berkman, MD, joins Vensana as a Partner after over a decade at Broadview Ventures, a […]
